Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million, with a minimum of RMB50 million allocated to A shares. As of the announcement date, Mr. Xiong Jun has already acquired 100,000 A shares, representing 0.01% of the company’s total share capital, through the Shanghai Stock Exchange. This move reflects confidence in the company’s future prospects, although the plan’s completion is subject to market conditions and other unpredictable risk factors.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, primarily engaged in the research, development, and commercialization of innovative drugs. The company focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic metabolic diseases, aiming to address unmet medical needs in these fields.
Average Trading Volume: 9,065,091
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.98B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.